Two Sigma Investments’s Rapport Therapeutics RAPP Stock Holding History

Two Sigma Investments’s Portfolio RAPP Stock Details RAPP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.02M	Sell	24,470 -3,633	-13%	-$134K	﹤0.01%	3603
2026 Q1	$879K	Sell	28,103 -22,516	-44%	-$633K	﹤0.01%	3357
2025 Q4	$1.54M	Buy	50,619 +29,119	+135%	+$806K	﹤0.01%	2641
2025 Q3	$639K	Buy	21,500 +1,757	+9%	+$31.3K	﹤0.01%	2868
2025 Q2	$224K	Sell	19,743 -14,014	-42%	-$149K	﹤0.01%	2877
2025 Q1	$339K	Buy	+33,757	New	+$438K	﹤0.01%	2667
2024 Q3	–	Sell	-13,000	Closed	-$302K	–	3380
2024 Q2	$302K	Buy	+13,000	New	+$301K	﹤0.01%	2592

Other funds holding RAPP

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

TGV

TRV GP V Boston, Massachusetts $498M AUM 267.53% 1-Year Est. Return

AVM

Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

Two Sigma Investments's RAPP Position: Q2 2026 in Review

Two Sigma Investments reduced its Rapport Therapeutics (RAPP) stake by 13% in Q2 2026, selling an estimated $134K and leaving 24,470 shares worth $1.02M. The position accounts for ﹤0.01% of the portfolio, ranked #3603.

Two Sigma Investments first reported a position in RAPP in Q2 2024 and has held it in 7 quarters since. The position peaked at $1.54M in Q4 2025. 160 funds tracked by Wall St. Rank hold RAPP as of Q2 2026.

Two Sigma Investments held 24,470 shares of Rapport Therapeutics worth $1.02M as of Q2 2026.
Two Sigma Investments sold 3,633 Rapport Therapeutics shares in Q2 2026, an estimated $134K.
Rapport Therapeutics made up ﹤0.01% of Two Sigma Investments's portfolio in Q2 2026, its #3603 holding.
Two Sigma Investments first reported a position in Rapport Therapeutics in Q2 2024 and has held it in 7 quarters since.
Two Sigma Investments's Rapport Therapeutics position peaked at $1.54M in Q4 2025.
160 funds tracked by Wall St. Rank held Rapport Therapeutics as of Q2 2026.

Based on Two Sigma Investments's 13F filing for Q2 2026, filed 14 Aug 2026.